Study protocol of RESCUE-ALS: A Phase 2, randomised, double-blind, placebo-controlled study in early symptomatic amyotrophic lateral sclerosis patients to assess bioenergetic catalysis with CNM-Au8 as a mechanism to slow disease progression

Introduction Amyotrophic lateral sclerosis (ALS) is an adult-onset, progressive and universally fatal neurodegenerative disorder. In Europe, Australia and Canada, riluzole is the only approved therapeutic agent for the treatment of ALS, while in the USA, riluzole and edaravone have been approved by...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	William Huynh, Steve Vucic, Parvathi Menon, Austin Rynders, Karen S Ho, Robert Glanzman, Michael T Hotchkin
Formato:	article
Lenguaje:	EN
Publicado:	BMJ Publishing Group 2021
Materias:	Medicine R
Acceso en línea:	https://doaj.org/article/5b34b89dba1c4672a117a2d5413de1b6
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:5b34b89dba1c4672a117a2d5413de1b6
record_format	dspace
spelling	oai:doaj.org-article:5b34b89dba1c4672a117a2d5413de1b62021-11-11T19:30:06ZStudy protocol of RESCUE-ALS: A Phase 2, randomised, double-blind, placebo-controlled study in early symptomatic amyotrophic lateral sclerosis patients to assess bioenergetic catalysis with CNM-Au8 as a mechanism to slow disease progression10.1136/bmjopen-2020-0414792044-6055https://doaj.org/article/5b34b89dba1c4672a117a2d5413de1b62021-01-01T00:00:00Zhttps://bmjopen.bmj.com/content/11/1/e041479.fullhttps://doaj.org/toc/2044-6055Introduction Amyotrophic lateral sclerosis (ALS) is an adult-onset, progressive and universally fatal neurodegenerative disorder. In Europe, Australia and Canada, riluzole is the only approved therapeutic agent for the treatment of ALS, while in the USA, riluzole and edaravone have been approved by the Food and Drug Administration (FDA) . Neither riluzole nor edaravone treatment has resulted in substantial disease-modifying effects. There is, therefore, an urgent need for drugs that result in safe and effective treatment. Here, we present the design and rationale for the phase 2 RESCUE-ALS study, investigating the novel nanocatalytic drug, CNM-Au8, as a therapeutic intervention that enhances the metabolic and energetic capacity of motor neurones. CNM-Au8 is an aqueous suspension of clean-surfaced, faceted gold nanocrystals that have extraordinary catalytic capabilities, that enhance efficiencies of key metabolic reactions, while simultaneously reducing levels of reactive oxygen species. This trial utilises a novel design by employing motor unit number index (MUNIX), measured by electromyography, as a quantitative measure of lower motor neurone loss and as an early marker of ALS disease progression.Methods and analysis This is a multicentre, randomised, double-blind, parallel group, placebo-controlled study of the efficacy, safety, pharmacokinetics and pharmacodynamics of CNM-Au8 in ALS patients. Patients will be randomised 1:1 to either receive 30 mg of CNM-Au8 once daily or matching placebo over a 36-week double-blind treatment period. Efficacy will be assessed as the change in motor neurone loss as measured by electromyography (eg, MUNIX, the primary endpoint; and secondary endpoints including MScanFit, motor unit size index, Split Hand Index, Neurophysiology Index). Exploratory endpoints include standard clinical and quality of life assessments.Ethics and dissemination RESCUE-ALS was approved by the Western Sydney Local Health District Human Research Ethics Committee (Ethics Ref: 2019/ETH12107). Results of the study will be submitted for publication in a peer-reviewed journal.Trial registration number NCT04098406William HuynhSteve VucicParvathi MenonAustin RyndersKaren S HoRobert GlanzmanMichael T HotchkinBMJ Publishing GrouparticleMedicineRENBMJ Open, Vol 11, Iss 1 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R
spellingShingle	Medicine R William Huynh Steve Vucic Parvathi Menon Austin Rynders Karen S Ho Robert Glanzman Michael T Hotchkin Study protocol of RESCUE-ALS: A Phase 2, randomised, double-blind, placebo-controlled study in early symptomatic amyotrophic lateral sclerosis patients to assess bioenergetic catalysis with CNM-Au8 as a mechanism to slow disease progression
description	Introduction Amyotrophic lateral sclerosis (ALS) is an adult-onset, progressive and universally fatal neurodegenerative disorder. In Europe, Australia and Canada, riluzole is the only approved therapeutic agent for the treatment of ALS, while in the USA, riluzole and edaravone have been approved by the Food and Drug Administration (FDA) . Neither riluzole nor edaravone treatment has resulted in substantial disease-modifying effects. There is, therefore, an urgent need for drugs that result in safe and effective treatment. Here, we present the design and rationale for the phase 2 RESCUE-ALS study, investigating the novel nanocatalytic drug, CNM-Au8, as a therapeutic intervention that enhances the metabolic and energetic capacity of motor neurones. CNM-Au8 is an aqueous suspension of clean-surfaced, faceted gold nanocrystals that have extraordinary catalytic capabilities, that enhance efficiencies of key metabolic reactions, while simultaneously reducing levels of reactive oxygen species. This trial utilises a novel design by employing motor unit number index (MUNIX), measured by electromyography, as a quantitative measure of lower motor neurone loss and as an early marker of ALS disease progression.Methods and analysis This is a multicentre, randomised, double-blind, parallel group, placebo-controlled study of the efficacy, safety, pharmacokinetics and pharmacodynamics of CNM-Au8 in ALS patients. Patients will be randomised 1:1 to either receive 30 mg of CNM-Au8 once daily or matching placebo over a 36-week double-blind treatment period. Efficacy will be assessed as the change in motor neurone loss as measured by electromyography (eg, MUNIX, the primary endpoint; and secondary endpoints including MScanFit, motor unit size index, Split Hand Index, Neurophysiology Index). Exploratory endpoints include standard clinical and quality of life assessments.Ethics and dissemination RESCUE-ALS was approved by the Western Sydney Local Health District Human Research Ethics Committee (Ethics Ref: 2019/ETH12107). Results of the study will be submitted for publication in a peer-reviewed journal.Trial registration number NCT04098406
format	article
author	William Huynh Steve Vucic Parvathi Menon Austin Rynders Karen S Ho Robert Glanzman Michael T Hotchkin
author_facet	William Huynh Steve Vucic Parvathi Menon Austin Rynders Karen S Ho Robert Glanzman Michael T Hotchkin
author_sort	William Huynh
title	Study protocol of RESCUE-ALS: A Phase 2, randomised, double-blind, placebo-controlled study in early symptomatic amyotrophic lateral sclerosis patients to assess bioenergetic catalysis with CNM-Au8 as a mechanism to slow disease progression
title_short	Study protocol of RESCUE-ALS: A Phase 2, randomised, double-blind, placebo-controlled study in early symptomatic amyotrophic lateral sclerosis patients to assess bioenergetic catalysis with CNM-Au8 as a mechanism to slow disease progression
title_full	Study protocol of RESCUE-ALS: A Phase 2, randomised, double-blind, placebo-controlled study in early symptomatic amyotrophic lateral sclerosis patients to assess bioenergetic catalysis with CNM-Au8 as a mechanism to slow disease progression
title_fullStr	Study protocol of RESCUE-ALS: A Phase 2, randomised, double-blind, placebo-controlled study in early symptomatic amyotrophic lateral sclerosis patients to assess bioenergetic catalysis with CNM-Au8 as a mechanism to slow disease progression
title_full_unstemmed	Study protocol of RESCUE-ALS: A Phase 2, randomised, double-blind, placebo-controlled study in early symptomatic amyotrophic lateral sclerosis patients to assess bioenergetic catalysis with CNM-Au8 as a mechanism to slow disease progression
title_sort	study protocol of rescue-als: a phase 2, randomised, double-blind, placebo-controlled study in early symptomatic amyotrophic lateral sclerosis patients to assess bioenergetic catalysis with cnm-au8 as a mechanism to slow disease progression
publisher	BMJ Publishing Group
publishDate	2021
url	https://doaj.org/article/5b34b89dba1c4672a117a2d5413de1b6
work_keys_str_mv	AT williamhuynh studyprotocolofrescuealsaphase2randomiseddoubleblindplacebocontrolledstudyinearlysymptomaticamyotrophiclateralsclerosispatientstoassessbioenergeticcatalysiswithcnmau8asamechanismtoslowdiseaseprogression AT stevevucic studyprotocolofrescuealsaphase2randomiseddoubleblindplacebocontrolledstudyinearlysymptomaticamyotrophiclateralsclerosispatientstoassessbioenergeticcatalysiswithcnmau8asamechanismtoslowdiseaseprogression AT parvathimenon studyprotocolofrescuealsaphase2randomiseddoubleblindplacebocontrolledstudyinearlysymptomaticamyotrophiclateralsclerosispatientstoassessbioenergeticcatalysiswithcnmau8asamechanismtoslowdiseaseprogression AT austinrynders studyprotocolofrescuealsaphase2randomiseddoubleblindplacebocontrolledstudyinearlysymptomaticamyotrophiclateralsclerosispatientstoassessbioenergeticcatalysiswithcnmau8asamechanismtoslowdiseaseprogression AT karensho studyprotocolofrescuealsaphase2randomiseddoubleblindplacebocontrolledstudyinearlysymptomaticamyotrophiclateralsclerosispatientstoassessbioenergeticcatalysiswithcnmau8asamechanismtoslowdiseaseprogression AT robertglanzman studyprotocolofrescuealsaphase2randomiseddoubleblindplacebocontrolledstudyinearlysymptomaticamyotrophiclateralsclerosispatientstoassessbioenergeticcatalysiswithcnmau8asamechanismtoslowdiseaseprogression AT michaelthotchkin studyprotocolofrescuealsaphase2randomiseddoubleblindplacebocontrolledstudyinearlysymptomaticamyotrophiclateralsclerosispatientstoassessbioenergeticcatalysiswithcnmau8asamechanismtoslowdiseaseprogression
_version_	1718431529918529536

Study protocol of RESCUE-ALS: A Phase 2, randomised, double-blind, placebo-controlled study in early symptomatic amyotrophic lateral sclerosis patients to assess bioenergetic catalysis with CNM-Au8 as a mechanism to slow disease progression

Ejemplares similares